GGrantIndex
← Leaderboards

Qibin Qi

Harvard University D/B/A Harvard School Of Public Health

$9,263,134
Attributed
$18,312,696
Total exposure
10
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.8M · FY201525
$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$18,312,696 · 10

By mechanism

R01$16,037,147 · 8
U01$1,638,162 · 1
K01$637,387 · 1

Top collaborators

Most similar at Harvard University D/B/A Harvard School Of Public Health

Same institution · by research overlap

Others in their field

Top investigators on “Cohort

Research focus

CohortMetabolomicsPathway InteractionsLinkGut MicrobiotaFollow-UpParticipantBiological MarkersInsightDietMetagenomicsPlasmaPreventionPathway AnalysisHealth StudyDiabetes MellitusCardiovascular DiseasesNurses&AposHispanic Community Health Study/Study Of LatinosBile AcidsFunctional DisorderMetabolismDiabetes RiskMicrobial

Grant awards (32)

Ultra-processed Foods, Diet Quality, and Cardiometabolic Health: An Inter-disciplinary Trans-Atlantic Collaborative Project$843,047
R01 · FY2025 · DK
Longitudinal omics-based trajectories of type 2 diabetes subtypes: the T2D Heterogeneity Consortium$814,689
U01 · FY2025 · DK
Identification of Biomarkers of Plant-Rich Diets and Carbonyl Stress and Their Associations with Cardiovascular Risk$733,785
R01 · FY2025 · HL
Multi-omic signatures of gut dysbiosis and cardiovascular comorbidities associated with HIV infection$705,769
R01 · FY2025 · HL · contact PI
Per- and polyfluoroalkyl substances, apolipoproteins, and risk of coronary heart disease$702,691
R01 · FY2025 · ES
Longitudinal omics-based trajectories of type 2 diabetes subtypes: the T2D Heterogeneity Consortium$823,473
U01 · FY2024 · DK
Per- and polyfluoroalkyl substances, apolipoproteins, and risk of coronary heart disease$765,745
R01 · FY2024 · ES
Multi-omic signatures of gut dysbiosis and cardiovascular comorbidities associated with HIV infection$700,116
R01 · FY2024 · HL · contact PI
Human Gut Microbiome and Incident Diabetes Risk in U.S. Populations$584,270
R01 · FY2024 · DK
Multi-omic signatures of gut dysbiosis and cardiovascular comorbidities associated with HIV infection$757,962
R01 · FY2023 · HL · contact PI
Human Gut Microbiome and Incident Diabetes Risk in U.S. Populations$608,080
R01 · FY2023 · DK
Human Gut Microbiome and Incident Diabetes Risk in U.S. Populations$608,080
R01 · FY2022 · DK
Metabolomics signatures underlying diet, lifestyle and gut microbiota for diabetes$556,810
R01 · FY2022 · DK · contact PI
Integrated analysis of CVD risk in HIV: gut microbiota, immune function and metabolites$777,067
R01 · FY2021 · HL · contact PI
Human Gut Microbiome and Incident Diabetes Risk in U.S. Populations$669,600
R01 · FY2021 · DK
Dietary Patterns and Risk of Cardiovascular Disease$667,451
R01 · FY2021 · HL
Metabolomics signatures underlying diet, lifestyle and gut microbiota for diabetes$556,810
R01 · FY2021 · DK · contact PI
Integrated analysis of CVD risk in HIV: gut microbiota, immune function and metabolites$790,750
R01 · FY2020 · HL · contact PI
Dietary Patterns and Risk of Cardiovascular Disease$663,685
R01 · FY2020 · HL
Metabolomics signatures underlying diet, lifestyle and gut microbiota for diabetes$556,810
R01 · FY2020 · DK · contact PI
Metabolomics signatures underlying diet, lifestyle and gut microbiota for diabetes$182,786
R01 · FY2020 · DK · contact PI
Integrated analysis of CVD risk in HIV: gut microbiota, immune function and metabolites$811,490
R01 · FY2019 · HL · contact PI
Dietary Patterns and Risk of Cardiovascular Disease$705,808
R01 · FY2019 · HL
Metabolomics signatures underlying diet, lifestyle and gut microbiota for diabetes$593,149
R01 · FY2019 · DK · contact PI
Integrated analysis of CVD risk in HIV: gut microbiota, immune function and metabolites$876,359
R01 · FY2018 · HL · contact PI
Dietary Patterns and Risk of Cardiovascular Disease$619,027
R01 · FY2018 · HL
HIV Infection, Metabolites and Subclinical Atherosclerosis$110,374
K01 · FY2018 · HL · contact PI
HIV Infection, Metabolites and Subclinical Atherosclerosis$61,876
K01 · FY2018 · HL · contact PI
HIV Infection, Metabolites and Subclinical Atherosclerosis$172,250
K01 · FY2017 · HL · contact PI
HIV Infection, Metabolites and Subclinical Atherosclerosis$154,782
K01 · FY2016 · HL · contact PI
HIV Infection, Metabolites and Subclinical Atherosclerosis$103,578
K01 · FY2015 · HL · contact PI
HIV Infection, Metabolites and Subclinical Atherosclerosis$34,527
K01 · FY2015 · HL · contact PI